Ramona Whittington From: Roxana Cruz Sent: Tuesday, April 20, 2021 5:59 PM To: Medical Directors; Dental Directors; [email protected]; [email protected]; Myrta Garcia; Lindsay Lanagan; catherine.threatt; Abby Villafane; Lynn Roberts; [email protected]; [email protected]; Dr Flower; Vicky Jefferson, Lone Star Circle of Care Cc: Jana Eubank; Daniel Diaz; Shelby Tracy; ClinicalTeam; Ramona Whittington Subject: COVID -19 Vaccine Weekly Update: Week 19 (04-19-2021) Attachments: COVID Therapeutics Monoclonalantibodychecklist.pdf; provider-covid-vaccine-factsheet.pdf; COVID-19 Vaccines FAQ_TACHC Apr2021.pdf; COVIDVaccineAllocation-Week19_HealthCenters.pdf Dear Fellow Directors and Vaccine Coordinators, Here is your COVID ‐19 Vaccine Weekly Update for Week 19 (04‐19‐2021) DSHS COVID Vaccine Allocations of 6,800 doses were made to 35 FQHC Health Center sites (see attached). This brings us to 189,465 doses allocated to approved 285 health center sites since roll‐out of the DSHS program. TACHC is working with DSHS to review data (ImmTrac2, VAOS, TDEM) for COVID‐19 vaccine allocations and administered doses on a weekly basis. Unfortunately, some significant discrepancies appear on the DSHS reports for a number of health centers…you are not alone. TACHC has developed a COVI‐19 FAQ for trouble shooting issues that arise related to administration and/or reporting vaccines (see attached). TACHC and HRSA encourage all health centers to join the HHS COVID-19 Community Corps. With everyone who is 16 or older now eligible for the COVID-19 vaccine, the Surgeon General shared a social media toolkit to make it easy for you to get the message out. Messaging: for updated, credible information on COVID‐19 vaccination, visit cdc.gov. For information about the HHS COVID‐19 Public Education Campaign, visit wecandothis.hhs.gov and hhs.gov/CovidCommunityCorps. HRSA Federal Vaccine Program allocations provided to: 35 Health Centers participating and 38 additional Health Centers invited to participate: https://www.hrsa.gov/coronavirus/health‐center‐program/participants/tx https://www.hrsa.gov/coronavirus/health‐center‐program HRSA Vaccine Program Open Office Hours on Wednesday at 1:00PM ET HRSA hosts an open office hour every Wednesday to share key information, discuss hot topics, and answer participants' questions. Check the VPC for more details and the Zoom link. We plan to continue to offer open office hours weekly at this same time. Access other events, including CDC hosted webinars, on the Upcoming Events Discussion Board in the VPC. Vaccine Updates: Overview of Health Center COVID‐19 Vaccinations Among Racial and Ethnic Minority Patients https://data.hrsa.gov/topics/health‐centers/covid‐vaccination All Americans at least 16 years old are now eligible for COVID‐19 vaccines. Texas is seeing a slight rise in new cases over the past week, with 1,073 new confirmed cases in the past 24 hours (https://txdshs.maps.arcgis.com/apps/dashboards/ed483ecd702b4298ab01e8b9cafc8b83) Recent COVID‐19 outbreaks in Michigan, Florida and other states have the whole country dreading a fourth surge in the pandemic; in a recent episode of the “AMA COVID‐19 Update,” Harris Pastides, PhD, MPH, an epidemiologist and president emeritus of University of South Carolina, laid out best practices for public health officials and physicians on the front lines. 1 Recommendation to Pause Use of Johnson & Johnson’s Janssen COVID‐19 Vaccine — CDC and FDA are reviewing data involving a small number of reported cases of a rare and serious type of blood clot in individuals after receiving the Johnson & Johnson/Janssen (J&J) vaccine. Out of an abundance of caution, a pause in the use of the J&J vaccine was recommended as CDC and FDA review this data. o Based on what is known, these blood clots are extremely rare. However, healthcare providers and individuals should be on alert for possible symptoms of a clot, which include severe headache, abdominal pain, leg pain, or shortness of breath. o Vaccine safety is a top priority for the federal government, and CDC takes all reports of health problems following COVID‐19 vaccination very seriously. Vaccine Adverse Event Reporting System (VAERS), is the nation’s established ‘early warning’ system for post licensure vaccine safety for both routine immunizations and COVID‐ 19 vaccines. Individuals that develop these symptoms within three weeks of receiving the J&J vaccine should seek medical care, and report the event to VAERS at https://vaers.hhs.gov/reportevent.html o The pause of the J&J vaccine does not affect the two other vaccines that are widely used in the United States ‐ Pfizer‐BioNTech or Moderna. For individuals who already have appointments for J&J vaccines, state and federal partners are working to get these appointments rescheduled for a Pfizer or Moderna vaccine. In accordance with HHS recommendation that vaccine providers pause on administering the Johnson & Johnson (J&J) COVID‐ 19 vaccine, HRSA will not accept new orders for Johnson & Johnson vaccine this week. For more information about the J&J vaccine visit: Recommendation to Pause Use of Johnson & Johnson’s Janssen COVID‐19 Vaccine | CDC Additional resources can be found below: Joint CDC and FDA Statement on Johnson & Johnson COVID‐19 Vaccine Joint Media Call: FDA & CDC to Discuss Janssen COVID‐19 Vaccine Dr. Fauci’s video on what people need to know about the J&J vaccine recommended pause Frequently Asked Questions about the J&J Vaccine Pause Frequently Asked Questions about VAERS Reporting for COVID‐19 Vaccines HRSA’s Fact Sheets for Patients and Providers on COVID‐19 Care for Uninsured Individuals In Case You Missed It Clinician Outreach and Communication Activity (COCA) – Johnson & Johnson/Janssen COVID‐19 Vaccine and Cerebral Venous Sinus Thrombosis with Thrombocytopenia – Update for Clinicians on Early Detection and Treatment — The Clinician Outreach and Communication Activity (COCA) held a call Thursday, April 15, 2021. During this COCA Call, participants received the latest evidence on cerebral venous sinus thrombosis (CVST) with thrombocytopenia associated with the administration of the Johnson & Johnson/Janssen COVID‐19 vaccine. Speakers discussed what is known about CVST, the importance of early detection, and updated vaccine recommendations. For more information, please visit: COCA Calls/Webinars Vaccine Administration Fees: (HRSA) What Providers Need to Know About COVID‐19 Vaccine Fees and Reimbursements (attached Fact Sheet) For Health Care Providers https://coviduninsuredclaim.linkhealth.com Uninsured Patient COVID Services Flyer (attached HRSA Flyer/Poster) For Patients https://www.hhs.gov/coronavirus/cares‐act‐provider‐relieffund/for‐patients Therapeutics: Monoclonal antibody therapies remain available under EUA, including REGEN‐COV (casirivimab and imdevimab, administered together), and bamlanivimab and etesevimab, administered together, for the same uses as previously authorized for bamlanivimab alone, which recently had its EUA revoked. https://www.fda.gov/news‐events/press‐ announcements/coronavirus‐covid‐19‐update‐fda‐revokes‐emergency‐use‐authorization‐monoclonal‐antibody‐ bamlanivimab https://www.idsociety.org/covid‐19‐real‐time‐learning‐network/therapeutics‐and‐interventions/monoclonal‐ antibodies/ Safety Checklist (ECRI): “Administration of Monoclonal Antibody Therapy for the Treatment of COVID‐19 in Non‐ hospitalized Patients” (see attached) 2 CDC Updates: CDC Partner Webinar: When to Clean, When to Disinfect, and What Science Says about SARS‐CoV‐2 on Surfaces | April 19, 2021, 2:00 pm CST — Dr. Cynthia Ogden will share updates on CDC’s COVID‐19 response, including the latest scientific information and what everyone should know about protecting themselves and others. Dr. Vincent Hill will discuss how SARS‐CoV‐2 impacts cleaning and disinfecting surfaces. Use this web‐link to register for this event. COVID Updates: As pandemic enters year 2, mental health burden becomes clearer One in three COVID‐19 long‐haulers experience anxiety, depression and more. Learn more about mental health and COVID‐19. Read more from the AMA. "Can COVID‐19 Vaccines Provide Relief For Long Haulers With Persisting Symptoms?". Click here to view: Can COVID‐ 19 Vaccines Provide Relief For Long Haulers With Persisting Symptoms? Updated: Healthcare Delivery Impacts Tip Sheet and Summary Document This updated tip sheet describes the short‐ and long‐term effects of COVID‐19 related community mitigation measures on the healthcare system, including morbidity and mortality from chronic health conditions and lack of access. The accompanying summary document can help healthcare system planners prepare to mitigate these potential healthcare delivery impacts. Webinars: “COVID‐19 Vaccine Update” Date: April 13 at 3 p.m. CT New webinar! Register now: Host: Susan R. Bailey, MD, president, AMA FREE WEBINAR FOR PUBLIC HOUSING AUTHORITIES AND COMMUNITY PARTNERS “A Vaccine Near You: Community‐Based Access Strategies” April 21, 2021 at 1:00 PM – 2:30 PM (CST) Please register for this webinar here. TACHC COVID‐19 Vaccine Administration Open‐House Call Wednesday April 28, 2021 @ 12:noon – 1:pm https://www.tachc.org/Online/Events/Event_display.aspx?EventKey=VACCADMIN&WebsiteKey=c7fdf3bd‐706d‐ 4253‐8852‐9535b5cf43c2 TACHC Registration link for the April 30th “Trusted Messengers: Let’s Talk Vaccines” webinar scheduled for Friday April 30, 2020 @ 12:noon ‐1:pm This presentation will provide health center staff with an opportunity to hear from Dr.